ORC5

Across TCGA pan-cancer cohorts, ORC5 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ORC5 data layer compared with 19 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher ORC5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ORC5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, OV, and DLBC are the cancer types where ORC5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	DFS	Median	All	0.250	0.903	<.001	36	view →
OV	OS	Median	II,III,IV	0.304	0.691	.030	18	view →
DLBC	OS	Median	All	0.054	0.842	<.001	12	view →
UCEC	DFS	Median	All	1.000	0.622	.022	6	view →
READ	OS	Median	All	0.527	0.932	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ORC5–BRCA (DFS)

Open the BRCA breakdown →